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Abstract
Background: RNAi is a prominent tool for the identification of novel regulatory elements within complex cellular pathways.
In invertebrates, RNAi is a relatively straightforward process, where large double-stranded RNA molecules initiate sequence-
specific transcript destruction in target cells. In contrast, RNAi in mammalian cell culture assays requires the delivery of short
interfering RNA duplexes to target cells. Due to concerns over off-target phenotypes and extreme variability in duplex
efficiency, investigators typically deliver and analyze multiple duplexes per target. Currently, duplexes are delivered and
analyzed either individually or as a pool of several independent duplexes. A choice between experiments based on siRNA
pools or multiple individual duplexes has considerable implications for throughput, reagent requirements and data analysis
in genome-wide surveys, yet there are relatively few data that directly compare the efficiency of the two approaches.
Methodology/Principal Findings: To address this critical issue, we conducted a direct comparison of siRNA pools and
multiple single siRNAs that target all human phosphatases in a robust functional assay. We determined the frequency with
which both approaches uncover loss-of-function phenotypes and compared the phenotypic severity for siRNA pools and
the constituent individual duplexes.
Conclusions/Significance: Our survey indicates that screens with siRNA pools have several significant advantages over
identical screens with the corresponding individual siRNA duplexes. Of note, we frequently observed greater phenotypic
penetrance for siRNA pools than for the parental individual duplexes. Thus, our data indicate that experiments with siRNA
pools have a greater likelihood of generating loss-of-function phenotypes than individual siRNA duplexes.
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Introduction
Reverse genetic studies are a dominant force in the functional
characterization of eukaryotic gene products in many pertinent
model systems. Unfortunately, such studies tend to be laborious,
costly and time-consuming in complex eukaryotic models. Thus,
whereas targeted loss-of-function studies are commonplace in
comparatively straightforward organisms such as yeast, in vivo
mutational analyses present considerable challenges in subjects of
a more immediate biomedical relevance such as mice. The recent
advent of the ‘‘RNA universe’’ fundamentally altered perspectives
for reverse genetic studies in mammalian systems. Specifically,
RNA interference (RNAi) bears the real promise of rapid and
directed genome-wide loss-of-function studies in a broad range of
cell culture models [1]. The principles of genome-scale RNAi
screens were first established in C. elegans and Drosophila melanogaster
and were later applied to mammalian systems [2,3,4]. Fortuitous
parallel developments of automated systems such as liquid
handling devices and high-throughput plate readers place
genome-wide studies of direct biomedical relevance within
immediate reach. For example, RNAi screens in mammalian cell
culture assays successfully probed topics as diverse as embryonic
stem cell self-renewal, West Nile virus infection and various aspects
of cancer progression [5,6,7,8,9]. Looking forward, progress in
assay miniaturization [10] and the establishment of high-content
systems makes it clear that more sophisticated assays are yet to
appear in the RNAi toolbox.
Despite these astounding developments, it is clear that RNAi is
not the ultimate panacea for the contemporary cell biologist. A
particular vexing issue that has not been fully addressed in siRNA
screens is the question of knock-down efficiency. In this context, a
major decision in every siRNA experiment is the amount of siRNA
duplexes to deliver for each gene target. Current conventions
suggest that a minimum of three siRNA duplexes that target non-
overlapping sections of the same gene product should be
employed. There are two theoretical advantages to such an
approach. First, as many siRNA duplexes fail to significantly
deplete their intended target, increased numbers of duplexes
should increase the likelihood of generating the true loss-of-
function phenotype for a particular gene. Furthermore, the ability
to probe a given target with multiple siRNA duplexes should
decrease the impact of off-target effects on hit identification, if one
sets a threshold that a minimum of two non-overlapping siRNA
duplexes should yield an overlapping phenotype [11]. Based on
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experiments is to test a minimum of three non-overlapping
duplexes and exclude all gene products that were not affected by a
minimum of two siRNA duplexes.
There are currently two approaches to test multiple siRNA
duplexes in genome-scale screens. In one case, each duplex is
tested individually. Whereas this approach requires considerable
commitments in terms of resources, it permits stratification of hits
into confidence groups based on the number of individual siRNA
duplexes that uncover a particular phenotype. The alternative
approach is to test all siRNA duplexes that target a given gene
product as a single pool. The obvious advantage to such an
approach is that it maximizes resources and increases throughput.
However, siRNA pool screens do not provide insights into the
number of individual siRNAs that contribute to a given phenotype
and the onus is on the investigator to test multiple single siRNA
duplexes in secondary assays specifically designed to probe false
positive rates. Both approaches are routinely applied in genome-
scale screens, yet the relative merits of siRNA pools and single
siRNA duplexes have not been tested in a systematic phenotypic
assay. Given the clear ramifications such considerations have for
screen execution, we consider this a critical issue.
Here, we present the results of a direct comparison of the
behavior of pooled and single siRNA duplexes in an unbiased
functional screen of the entire set of human phosphatases. Our
data indicate that the apparent hit frequency is higher in screens
performed with siRNA pools and that phenotypes from siRNA
pools are often more pronounced than phenotypes for the
corresponding individual siRNA duplexes. These observations
combined with the advantages represented by siRNA pools in
terms of throughput and reagent consumption, lead us to propose
that siRNA pools are a superior tool for genome-scale siRNA
screens.
Results
A Quantitative siRNA-Based Assay for Modifiers of
TNF-Dependent Cell Death
We developed a quantitative plate-based assay to identify
siRNA duplexes that modify cellular responses to the Tumor
Necrosis Factor-a (TNF) cytokine. Engagement of the Tumor
Necrosis Factor Receptor (TNFR) by homotrimeric TNF ligands
drives the activation of JNK, NF-kB and caspase signal
transduction cassettes. NF-kB family members promote the
transcription of ‘‘pro-survival’’ gene products that contribute to
inflammatory responses, induce cellular proliferation and differ-
entiation and actively block caspase-mediated pro-apoptotic
events. In the absence of NF-kB-responsive gene products, TNF
signal transduction results in apoptotic cell death through the
caspase cascade.
We used a defined set of siRNA duplexes to probe the entire
annotated collection of human phosphatases (265 individual genes)
for modifiers of TNF-dependent cell death. The layout of each
siRNA master plate is shown in Figure 1A. Each plate contained
80 experimental siRNA duplexes that target defined phosphatases.
In addition, each master plate contained multiple control wells,
such as no siRNA duplexes, a non-silencing control siRNA duplex
and positive control siRNA duplexes that target NEMO or
caspase-8. We chose NEMO and caspase-8 as controls, as they are
essential for the activation of NF-kB or the induction of apoptotic
Figure 1. A plate-based siRNA screen for modifiers of TNF-induced cell death. (A) Phosphatase siRNA plate layout for each plate of the
screen. Positive control siRNAs target caspase-8 or NEMO and negative control siRNAs do not silence any cellular target. (B) Schematic representation
of screen preparation and workflow. The ratio of the viability score from untreated cells to the viability of treated cells represents the TNF-induced
death (death index). (C) Viability measurements for replicate assays. The viability scores for each plate are plotted against the viability scores of the
corresponding replicate. Plots represent the comparison of replicate plates incubated with either single or pooled siRNAs and treated with TNF/
Cycloheximide (CHX) as indicated.
doi:10.1371/journal.pone.0008471.g001
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target gene: three plates contained unique non-overlapping siRNA
duplexes and the fourth plate contained a pool of the three
individual duplexes. Each master plate was prepared in such a way
that all plates contained equimolar concentrations of total siRNA.
We then screened each plate for modifiers of TNF-dependent
cell death. The screen layout is described in Figure 1B. We treated
two replicate plates with TNF and non-lethal doses of the
translation inhibitor cycloheximide. The combined regime
attenuates the expression of NF-kB responsive anti-apoptotic
factors and is a widespread method for the induction of TNF-
responsive cell death in a number of different cell lines. We
quantified cell viability in each well under the respective culture
conditions in a resazurin cell viability assay and normalized each
viability score to the mean of the non-silencing control siRNA on
the same plate. Normalization allowed us to perform plate-to-plate
comparisons and develop a comparable ‘‘death index’’ to assess
the level of TNF-induced death for each siRNA under scrutiny.
Analysis of replicate measurements confirmed that the over-
whelming majority of the cell viability measurements was
reproducible (Figure 1C). Control caspase-8 siRNAs reliably
blocked TNF/cycloheximide-dependent cell death, while NEMO
siRNAs reproducibly increased TNF/cycloheximide-dependent
death. Both phenotypes are consistent with the respective roles of
caspase-8 and NEMO in the induction or inhibition of TNF-
dependent apoptosis. Statistical evaluation of screen data con-
firmed that the overall screen quality was high [12]. In summary,
we are confident that the assay represents a valid springboard for
the identification of siRNA duplexes that modify TNF-dependent
cell death.
Statistical Evaluation of Screen Data
We then plotted the death index for each siRNA from the
primary screen (Figure 2). The corresponding raw viability
measurements are available in Table S1. For statistical purposes,
we defined a modifier siRNA as an siRNA duplex that produced a
death index greater than 1.96 standard deviations above the
median non-silencing control siRNA. These criteria define the 95
percent confidence interval for true modifier siRNAs and are
routinely applied for ‘‘hit’’ identification in high-throughput RNAi
screens. As we consider assaying a pool of three siRNA duplexes a
distinct experimental approach to an assay that probes each
siRNA duplex separately, we identified modifier siRNA pools and
modifier single siRNA duplexes separately. Current standards for
experiments with single siRNA duplexes dictate that a minimum
of two non-overlapping siRNAs are required to produce
overlapping phenotypes before the target gene product should
be considered a valid modifier. Based on these critieria, we defined
two separate categories of modifier single siRNAs: a high-
confidence set, where all three siRNAs fell within the 95%
confidence interval; and a medium-confidence set, where two of
three siRNAs fell within the 95% confidence interval.
A Comparison of Hits from the Single and Pooled siRNA
Duplexes
We then compared modifier gene products identified through
pooled siRNAs and single siRNA assays. From these comparisons,
we distinguished three broad classes of putative hits: ‘‘dual’’ hits,
where the pool and a minimum of two single siRNA duplexes
identified the target as a modifier; ‘‘pool only’’ hits, where only the
pooled siRNA identified the target as a modifier; and ‘‘single only’’
hits, where a minimum of two single siRNA duplexes identify the
target as a hit, but the pooled siRNA does not (Table 1). In total,
we identified thirty three putative hits from the siRNA pools and
nineteen putative hits from the individual siRNA duplexes, of
which three were high-confidence modifiers and sixteen were
medium-confidence modifiers (Figure 3A and B). Thus, while we
detected a general overlap between both screens in terms of ‘‘hit’’
identification, our survey indicates that the frequency of hit
identification is considerably higher for screens performed with
siRNA pools.
Phenotypic Distinctions between Screens with siRNA
Pools and Screens with Single siRNA Duplexes
The greater apparent frequency of hits in screens performed
with siRNA pools prompted us to examine the severity of the
phenotypes described for pooled and single siRNA duplexes. To
this end, we arranged each gene product in descending order of
death index from the pooled screen and plotted the range of death
indices for the single siRNA duplexes that target the same gene
product (Figure 4A). A cursory examination of the corresponding
death indices reveals a broad range of death indices for a large
number of single siRNAs that target a common gene. This is a
common feature of individual siRNA molecules and likely reflects
that fact that many siRNA duplexes fail to significantly deplete the
target protein.
We were surprised to note that the death index attributed to
siRNA pools often fell outside the range of death indices attributed
to the corresponding set of individual siRNA duplexes. In total, we
identified 82 of 265 cases (31%) where the death index of the
siRNA pool did not overlap with the range of death indices for the
corresponding individual siRNA duplexes. Close examination of
the siRNA pools with death indices outside the corresponding
single siRNA ranges revealed a particularly intriguing feature. We
divided the siRNA pools into five equally sized groups (53 pools
per group) that ranged from pools with the highest death index to
pools with the lowest death index (Figure 4A). In the group of
pools with the highest death indices, 25 had death indices that
were outside the range of the corresponding single siRNA
Figure 2. Two siRNA screening approaches identify modifiers
of TNF-induced cell death. Target genes are shown on the x-axis in
the order screened with each corresponding experimental viability
score normalized and plotted as a distribution in the y-axis around the
mean viability score of the non-silencing siRNA plate control, which was
set to a death index of one. The 95% and 99% confidence intervals
shown represent the probability threshold of TNF modifiers amongst
the single siRNAs screened. The death indices of control siRNAs from
each master plate are shown.
doi:10.1371/journal.pone.0008471.g002
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Accession GENE ID GENE NAME Hit Validity
Hit
Confidence Pool siRNA 1 siRNA 2 siRNA 3
NM_000151 G6PC glucose-6-phosphatase, catalytic Dual Hit High 2.9003 1.8459 2.1934 2.3147
NM_138793 ENTPD8 calcium activated nucleotidase 1 2.3062 2.3315 2.0295 2.4356
NM_004090 DUSP3 dual specificity phosphatase 3 Medium 2.2307 2.2403 1.8716 1.3754
NM_021176 G6PC2 glucose-6-phosphatase, catalytic, 2 2.1342 1.1284 1.8567 2.4528
NM_012229 NT5C2 5-nucleotidase, cytosolic II 2.1316 1.2446 2.2222 2.9737
NM_178003 PPP2R4 protein phosphatase 2A, regulatory subunit B 2.1239 1.2425 2.0035 2.6130
NM_002480 PPP1R12A protein phosphatase 1, regulatorysubunit 12A 2.1128 1.4400 1.9571 2.4310
NM_014678 KIAA0685 KIAA0685 1.9730 2.0715 1.2485 2.2899
NM_004566 PFKFB3 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 1.9234 1.7908 1.5559 1.8546
NM_206873 PPP1CA protein phosphatase 1, catalytic subunit, alpha isoform 1.8867 1.8826 2.0215 1.4203
XM_497574 LOC342853 – Pool Only Low 2.9180 1.5194 1.6771 3.0943
XM_498334 LOC442428 – 2.2651 0.9931 2.2196 1.1948
NM_144648 FLJ32786 FLJ32786 2.2541 2.2595 1.3660 1.1998
NM_003837 FBP2 fructose-1,6-bisphosphatase 2 2.1309 2.2476 1.2325 1.0972
NM_005730 CTDSP2 RNA pol. II c-terminal domain, polypeptide A small
phosphatase 2
2.1289 1.9402 1.0854 1.5817
NM_005340 HINT1 histidine triad nucleotide binding protein 1 2.1233 1.0903 2.4192 1.2247
NM_032593 HINT2 histidine triad nucleotide binding protein 2 2.0986 1.4094 1.3917 3.1661
NM_001776 ENTPD1 ectonucleoside triphosphate diphosphohydrolase 1 2.0248 2.5402 1.5904 0.9978
NM_181843 NUDT8 nucleoside diphosphate linked moiety X-type motif 8 2.0241 2.3944 1.3122 0.7565
NM_006241 PPP1R2 protein phosphatase 1, regulatory subunit 2 1.9775 2.3725 1.2826 1.6937
NM_007099 ACP1 acid phosphatase 1, soluble 1.9499 1.6933 1.8857 1.4492
XM_497141 LOC441511 – 1.9292 1.6908 1.5069 1.8579
NM_080841 PTPRA protein tyrosine phosphatase, receptor type, A 1.8600 1.1012 1.9511 1.4844
NM_005192 CDKN3 cyclin-dependent kinase inhibitor 3 1.7696 1.3822 0.8408 2.0323
NM_080876 DUSP19 dual specificity phosphatase 19 1.7569 1.7371 1.5304 1.5611
NM_002717 PPP2R2A protein phosphatase 2, regulatory subunit B, alpha isoform Zero 1.8898 1.2037 1.7246 1.6531
NM_006212 PFKFB2 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 2 1.8793 1.2788 1.3083 1.6599
XM_374879 PTPMT1 protein tyrosine phosphatase, mitochondrial 1 1.8792 1.5690 1.4851 1.6204
NM_199255 TPTE2 Transmemb. phosphoinositide 3-phosphatase & tensin
homolog 2
1.8629 1.6875 0.8722 1.2343
NM_022097 LOC63928 LOC63928 1.8397 1.3315 1.2093 1.4714
NM_001030059 PPAPDC1A phosphatidic acid phosphatase type 2 domain
containing 1A
1.7969 1.2003 1.2035 1.4436
NM_001248 ENTPD3 ectonucleoside triphosphate diphosphohydrolase 3 1.7852 1.3722 1.4811 0.9802
NM_001567 INPPL1 inositol polyphosphate phosphatase-like 1 1.7479 1.1947 1.5363 1.1470
NM_001948 DUT dUTP pyrophosphatase Singles Only High 1.1402 1.7850 1.9004 1.8668
NM_000507 LOC390760 – Medium 1.6718 1.4416 1.9962 1.9126
NM_002012 FHIT fragile histidine triad gene 1.5280 2.0044 1.3869 1.9565
NM_144714 FLJ25449 FLJ25449 1.5197 1.7870 1.9786 1.4684
NM_015466 PTPN23 protein tyrosine phosphatase, non-receptor type 23 1.4990 1.8296 1.1512 1.8577
NM_001004318 FLJ16165 FLJ16165 1.4731 2.1641 1.9933 1.4317
NM_014431 PALD KIAA1274 1.3414 1.9367 2.4109 1.1976
NM_203453 LOC403313 LOC403313 1.2974 1.4860 2.3583 1.7807
XM_498243 LOC442350 – 1.0191 1.8247 2.2319 1.2570
The death index for each pool and single siRNA are shown in the final four columns. Putative hits are divided into groups according to the screens in which they were
identified as modifiers. Putative modifiers are further subdivided into confidence intervals based on the number of single siRNAs that give a particular phenotype. In the
pool only list, low confidence hits are genes for which a single siRNA gave a significant modifier phenotype, and zero confidence hits were not significantly modified by
any single siRNA.
doi:10.1371/journal.pone.0008471.t001
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pools was greater than the maximum death index of the individual
siRNA duplexes (Figure 4B). We noticed an identical phenomenon
when we examined the opposite end of the phenotypic spectrum.
Of the 53 pooled siRNAs with the lowest death index, 18 had
death indices that were outside the range of the corresponding
single siRNA duplexes. In each case, the death index for the
siRNA pool was lower than the lowest death index identified for
the corresponding single siRNA duplexes. These data suggest that
the phenotypic penetrance of siRNA pools often exceeds the
phenotypic penetrance of any one of the corresponding single
siRNA duplexes.
A Comparison of Pooled and Single siRNA Screen Data
The frequent disparity between phenotypic penetrance for single
duplexes and siRNA pools led us to question the phenotypic
relationship between both methods of siRNA delivery. For these
comparisons, we postulated that a phenotype from an siRNA pool
may represent the mean phenotype of the individual siRNA
duplexes; the median phenotype of the individual duplexes; or the
optimal phenotype of the individual duplexes. To distinguish these
possibilities, we plotted the death indices for the siRNA pools
against the mean, median and optimal death indices from the
corresponding single siRNA duplexes. We considered two possible
definitions of ‘‘optimal’’ phenotype: one where the siRNA duplex
with the most extreme death index constitutes the optimal death
index (single optimal); and one where the mean of the two greatest
death indices from the single siRNA duplexes constitute the optimal
death index (cumulative optimal). The former definition favors a
scenario where a very limited number of highly efficient on-target
siRNAs determine the loss-of-function phenotype. The latter
definition is more biased to a scenario where the loss-of-function
phenotype represents the cumulative effect of all on-target siRNAs.
For each scenario, we determined the correlation coefficient and
used paired students t-tests to determine the significance of overlap
between the two death indices. In each case, we noticed a general
overlap between the corresponding death indices (Figure 5A–D).
These data indicate a broad phenotypic consensus between siRNA
pools and multiple siRNA duplexes and argue that screens with
siRNA pools are equally efficient at generating loss-of-function
phenotypes as screens performed with multiple individual siRNAs.
Strikingly, paired students t-tests revealed a significant phenotypic
correlation between siRNA pools and the optimal death index
(cumulative or single) for the corresponding single siRNA
duplexes. Thus, it appears that siRNA pools often generate the
maximal phenotype for the corresponding single duplexes.
Discussion
RNAi-based loss-of-function studies open entirely new perspec-
tives in cell biology, particularly for the identification of
biomarkers or pharmacologically relevant targets in critical disease
states. As with many genetic techniques, groundbreaking studies in
the model invertebrates C. elegans and Drosophila melanogaster guided
subsequent developments in mammalian systems. In Drosophila and
C. elegans, RNAi involves the introduction of large dsRNA
molecules typically greater than 250 bp into target cells. The
large duplexes are diced internally into numerous small 21mer
duplexes, which feed the classical RISC/RNAi pathway. Thus,
RNAi experiments in invertebrates are, by design, performed with
large pools of individual siRNA duplexes.
As large dsRNA molecules induce non-specific interferon
responses in mammalian cell lines [13], alternative strategies are
required for targeted knock-down studies. Typically, investigators
use lipid-based or viral vehicles to deliver a small number (1 to 4) of
non-overlapping siRNAs to target cells. These siRNA molecules are
either delivered individually or as pools. Despite the clear
experimental differences between the separate delivery of multiple
individual duplexes and a pool of the same duplexes, there are very
littledataonthe phenotypicconsequencesofsuchanapproach. The
bulk of recommendations on the relative advantages and disadvan-
tages of pooled or single siRNAs are given by product vendors with
vested commercial interests in the outcome. For example, a recent
review of siRNA technologies specifically discussed the relative
meritsofpooledversussinglesiRNAsfromtheperspectiveofvarious
commercial vendors of siRNA libraries [14]. Unsurprisingly, the
opinions were immediately aligned with the product portfolio of the
individual companies – the leading vendor of siRNA pools
recommended pools and vendors of individual duplexes strongly
cautionedagainsttheuseofpools.Inthisstudy,we setouttoprepare
an unbiased comparison of the phenotypes generated by siRNA
Figure 3. Relationship between putative hits from siRNA pools
or single siRNA duplexes. (A) The number and relation of gene
target hits from single and pooled siRNA screens. The Venn diagram
shows high and medium confidence hit groups from the single siRNA
screen and indicates the degree to which each group overlaps with the
siRNA pool hits. (B) Hierarchical cluster analysis of pool screen hits and
medium to high confidence interval single screen hits. The death index
of siRNA targets are clustered on a color scale ranging from the highest
death index value, depicted as yellow, to the lowest death index value,
depicted as black, and centered around the non-silencing control
assigned a death index of one, depicted as red. Group I represents
medium confidence single siRNA hits. Group II represents all putative
hits identified in the pool and medium confidence single siRNA screen.
Group III represents all putative hits identified in the pool screen only.
Group IV represents all putative hits identified in the pool and high-
confidence single siRNA screen. Group V represents high confidence
single siRNA hits.
doi:10.1371/journal.pone.0008471.g003
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Given the tremendous potential of siRNA screens for the
identification of biomarkers or pharmacological targets and the
explosive growth in prominent studies based on high-throughput
siRNA studies, we believe our findings are of considerable value to a
large community of biological researchers.
Perhaps the most significant aspect of our findings is the fact that
the phenotypic penetrance for siRNAs pools is frequently more
severe than for any of the parental siRNA duplexes. Evaluation of
our phenotypic data suggests that the phenotype associated with a
pool of siRNAs most closely resembles the cumulative functional
phenotype of the parental siRNA duplexes. The most parsimonious
explanation for this observation is that the effective target knock-
down achieved with an siRNA pool is a combination of the knock-
downs achieved by the constituent duplexes. Thus, in a case where
several individual duplexes yield partial knock-downs that are
Figure 4. Comparison of single and pooled siRNA screens reveals the level of phenotypic penetrance for each siRNA. (A) A
distribution of the death indices of single and pooled siRNAs. Genes are sorted from greatest to lowest siRNA pool death indices. The range of death
indices attributed to the corresponding individual siRNAs are shown for each gene. (B) Graphic representation of non-overlapping phenotypes for
pools and corresponding single siRNAs. Pooled siRNAs were sorted into five equally sized groups of decreasing death indices. The amount of pools
with death indices higher than the maximal corresponding single siRNA are shown for each group as black columns. The amount of pools with death
indices lower than the minimal corresponding single siRNA are shown for each group as grey columns.
doi:10.1371/journal.pone.0008471.g004
Figure 5. Comparative analysis of all pooled siRNA and single siRNA death indices. (A) The x-axis shows the mean death index of all three
siRNAs tested per gene. (B) The x-axis shows the median death index of all three siRNAs tested per gene. (C) The x-axis shows the greatest single
death index of all three siRNAs tested per gene. (D) The x-axis shows the mean of the two greatest death indices of all three siRNAs tested per gene.
The correlation and statistical significance between the death index values of the mean single and pooled siRNA is indicated.
doi:10.1371/journal.pone.0008471.g005
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individual knock-downs may translate into a more robust and
detectable phenotype. Most siRNA design algorithms are based on
empirical observations of the sequence composition of effective on-
target siRNAs. Advances in siRNA design algorithms allow vendors
to make general guarantees about the likelihood of transcript
destruction upon the purchase of a set of non-overlapping siRNAs
that target a specific transcript. However, it is not possible to predict
the success of each individual siRNA, as the exact cellular context in
which siRNAs interact with target transcripts remains unresolved.
For example, siRNA design algorithms do not address critical issues
such as secondary structures within specific target transcripts or
accessibility issue presented by RNA protein complexes. siRNA
pools may partially compensate for these shortcomings by
combining several weak knock-down phenotypes to generate a
more penetrant phenotype.
As siRNA pools often generate more penetrant phenotypes than
any of the corresponding single duplexes, we also expect that
screens with pools will identify a greater number of putative hits in
the primary screen. Consistent with this hypothesis, we note that
standard analysis of our siRNA pool data identified 33 putative
hits (12% hit rate), while analysis of our single siRNA data
identified 16 medium-confidence hits (6% hit rate) and only three
high-confidence hits (1% hit rate). Based on our own work and
data from other siRNA screens, we consider it highly probable that
some of the putative hits from the siRNA pools are false positives.
However, we believe that the effort required to identify false
positives in secondary analysis is preferable to the loss represented
by false negatives in misguided primary analysis.
In summary, our data argue that screens performed with siRNA
pools identify a larger set of hits than screens performed with single
siRNA duplexes and that the phenotypic penetration for siRNA
pools is often greater that any of the individual siRNAs. Thus, we
conclude that screens with siRNA pools represent an optimal
approach in terms of phenotypic strength, throughput and reagent
efficiency.
Materials and Methods
siRNA Library of Human Phosphatases
To obtain the targeted knockdown of 265 phosphatases we used
the Ambion SilencerH human phosphatase-specific siRNA library
(Applied Biosystems). The library is composed of three sequence-
independent siRNAs per gene target and was handled according to
manufacturer’s protocol. To obtainthe pooled siRNA library, equal
volumes from all three target-redundant single siRNA libraries were
combined. The single and pooled siRNA libraries were prepared to
stock concentrations of 200 nM, thereby establishing the concen-
tration of each unique siRNA in the pooled library at 66.67 nM.
Single and Pooled siRNA Screens Using the Resazurin
Viability Assay
For siRNA library screening in a 96 well plate format, all steps
were performed on a sterile automated liquid handling platform
(JanusH PerkinElmer). HeLa cells of an identical passage number
at 8.67610
4 cells/ml were reverse transfected with siRNA at a
final concentration of 20 nM using DharmaFect 1 transfection
reagent (Dharmacon). After transfection, cells were incubated with
siRNA under standard mammalian cell culture conditions for
72 h. Following the RNAi incubation period, cells were either
treated with cell culture medium alone or with a mixture of Tumor
Necrosis Factor alpha (Roche) and Cyclohexamide (Sigma) in
culture medium to a final concentration of 20 ng/ml and 5mg/ml
respectively. The redox dye, resazurin (Sigma), was added to cells
13.5 h after treatment and incubated with cells for 1.5 h before
reading fluorescence signal on a multi-label plate reader
(EnVisionH PerkinElmer).
Statistical and Graphical Analyses
To analyze the screen data, confidence intervals were
established from the standard deviation of the single siRNA
screens from the non-silencing control siRNA on the respective
plates. To establish a simplified view of gene clusters with
differential involvement in modulating TNF/CHX-induced death,
cluster analysis was performed using the Cluster 3.0 program.
Data from 265 normalized death indices measured from single
and pooled screens were organized by hierarchical clustering.
Euclidean distance between normalized death indices was used as
the metric. The results of this cluster analysis are represented as a
heatmap generated by Java TreeView 1.1.3.
Supporting Information
Table S1 Normalized viability scores and death indices for each
individual siRNA and all siRNA pools.
Found at: doi:10.1371/journal.pone.0008471.s001 (0.27 MB
XLS)
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